Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beyond AirXAIR -4.72%25 Receivables Turnover is 1.70 as of Mar. 2026. GuruFocus rates XAIR with a GF Score™ of 25/100 and a GF Value™ of $134.81 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 811 Medical Devices & Instruments companies, Beyond Air ranks better than 80.39% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Beyond Air's Revenue for the
three
months ended in Mar. 2026 was $1.91 Mil. Beyond Air's average Accounts Receivable for the
three
months ended in Mar. 2026 was $1.12 Mil.
Hence, Beyond Air's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.70.
Beyond Air (NAS:XAIR) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Beyond Air Receivables Turnover Related Terms
Beyond Air Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Beyond Air's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XAIR vs VVOS, TNON, BMRA: Receivables Turnover Comparison
For the Medical Devices subindustry, Beyond Air's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beyond Air Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Beyond Air's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Beyond Air's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beyond Air (XAIR) has a Receivables Turnover of 1.70 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Beyond Air and its competitors. According to the industry distribution chart, Beyond Air ranks #159 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 19.6%.
Is Beyond Air's Receivables Turnover too high?
Beyond Air's current Receivables Turnover is 1.70. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Beyond Air's value of 1.70 is 69.1% below this industry median. Based on the distribution chart, Beyond Air ranks #159 out of 811 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Beyond Air has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Beyond Air's Receivables Turnover compare to VVOS and TNON?
According to the Medical Devices & Instruments industry distribution chart, Beyond Air ranks #159 out of 811 companies for Receivables Turnover. This places Beyond Air in the top 20% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.51. Beyond Air's value of 1.70 is 69.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beyond Air's current Receivables Turnover of 1.70 is 69.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Beyond Air and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beyond Air's current Receivables Turnover is 1.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beyond Air stock overvalued right now?
Based on GuruFocus' analysis, Beyond Air (XAIR) is currently considered Possible Value Trap. The stock's GF Value™ is $134.81, compared to a current price of $5.65 — trading 95.8% below its estimated fair value. The current Receivables Turnover is 1.70 and 69.1% below the Medical Devices & Instruments industry median of 5.51. Beyond Air's overall GF Score™ is 25/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Beyond Air (XAIR), the current Receivables Turnover is 1.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beyond Air (XAIR) Overvalued in 2026?
Based on GuruFocus' analysis, Beyond Air stock appears to be undervalued.
The current stock price of $5.65 is trading 95.8% below its estimated GF Value™ of $134.81.
GuruFocus considers Beyond Air to be Possible Value Trap.
Key valuation signals for XAIR:
Receivables Turnover: 1.70
GF Value™: $134.81 vs. price of $5.65 (95.8% below fair value)
Industry Position: 69.1% below the Medical Devices & Instruments median (#159 of 811)
No single metric tells the full story. See the XAIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
25GF Score
Get the complete analysis for XAIR
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XAIR has been successfully added to your 
